We are focusing on the development of global new medicine.
RESEARCH & DEVELOPMENT
Major Achievement
Through persistent effort and passion for new drug development, DongA ST has attained notable success in creating numerous proprietary new drugs.
It began with the launch of the first new drug, Stillen, in 2002, followed by Zydena, Motilitone, Sivextro, and Suganon/Sugamet.
We have achieved remarkable milestones with continuous investment in R&D, including numerous international paper publications,
active participation in global conferences, and a consistent record of filing and registering patents.
8 Biologics
-
Interferon-alfa 1994
IFN-α for immunology
-
Growtropin®1999
hGH for stimulating growth
-
Eporon®1999
EPO for anemia
-
Leucostim®1999
G-CSF for low neutrophil count PEG-G-CSF for longer activity
-
Dulastin®2015
G-CSF for low neutrophil count PEG-G-CSF for longer activity
-
Gonadopin®2006
FSH for stimulating fertilization
-
Darbepoetin alfa 2019
Nesp® Biosimilar for anemia, Launched in Japan by SKK
-
IMULDOSA™ 2024 STELARA® Biosimilar
Biosimilar launched by Accord BioPharma in the United States
3 NCEs
-
Zydena®2005
Erectile dysfunction
-
Sivextro® 2014
Infections, Launched Globally by MSD
-
Suganon® 2016
T2DM, Launched in Korea, Russia, India, and Brazil
-
Sugamet® 2016
T2DM, Launched in Korea, Russia, India, and Brazil
2 Botanical drugs
-
Stillen® 2002
Gastritis
-
Motilitone® 2011
Functional dyspepsia